Form 10-Q Summary
Source discrepancy: The request identifies Ocugen, Inc., but the filing text is for Histogenics Corporation (Commission File No. 001-36751). The summary below reflects the filing text provided.
Business Context and Reporting Period
Histogenics is a regenerative medicine company developing musculoskeletal products, principally NeoCart, an investigational cartilage-repair product in a 245-patient U.S. Phase 3 clinical trial under an FDA Special Protocol Assessment. Management expected to complete enrollment in the second quarter of 2016. NeoCart was not approved for sale in any jurisdiction as of June 30, 2015.
The unaudited Form 10-Q covers the three and six months ended June 30, 2015, with comparisons to the corresponding 2014 periods. The company had 13,236,814 common shares outstanding as of August 10, 2015 and reported no revenue from its planned principal operations in the financial statements.
Financial Performance and Position
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Research and development expense | $5.9 million, versus $4.7 million | $11.6 million, versus $8.0 million |
| General and administrative expense | $1.7 million, versus $1.3 million | $3.8 million, versus $3.1 million |
| Total operating expenses | $7.6 million, versus $6.0 million | $15.5 million, versus $11.2 million |
| Net loss | $7.6 million, versus $8.3 million | $15.6 million, versus $11.7 million |
| Loss per share | $0.58, versus $19.85 | $1.18, versus $25.91 |
The company had no meaningful operating revenue, so revenue and operating margins were not meaningful. Operating loss was $7.6 million for the quarter and $15.5 million for the six-month period. The accumulated deficit was $149.1 million at June 30, 2015.
- Cash and cash equivalents were $45.2 million at June 30, 2015, down from $58.1 million at December 31, 2014.
- Total assets were $53.2 million and total liabilities were $9.4 million at June 30, 2015.
- Stockholders’ equity was $43.9 million, compared with $54.2 million at year-end 2014.
- Equipment-loan borrowings were approximately $1.64 million, including $0.58 million classified as current and $1.05 million as long-term.
- The company was in compliance with the equipment-loan covenants and had no off-balance-sheet arrangements.
Cash Flow and Liquidity
| Six-Month Cash Flow | 2015 | 2014 |
|---|---|---|
| Cash used in operating activities | $(16.2) million | $(10.5) million |
| Cash used in investing activities | $(1.3) million | $(0.2) million |
| Cash provided by financing activities | $4.6 million | $9.7 million |
| Net decrease in cash | $(12.8) million | $(1.0) million |
Operating cash use increased primarily because of higher research and development spending and changes in working capital. Investing cash use increased due to laboratory equipment and leasehold-improvement purchases. Financing cash inflow in 2015 primarily reflected $4.7 million of net proceeds from the partial exercise of the IPO overallotment option.
Management stated that existing cash and cash equivalents were expected to fund projected needs into 2017, but additional capital would be required for continued product development and potentially sooner for other development activities.
Material Changes Versus the Prior Comparable Period
- Second-quarter research and development expense increased 25%, primarily due to NeoCart trial enrollment, Lexington facility costs, consulting, and personnel expenses.
- Six-month research and development expense increased 44%, reflecting higher clinical-trial enrollment, consulting, personnel, depreciation, stock compensation, and materials costs.
- General and administrative expense increased 29% for the quarter and 22% for the six-month period, driven by higher insurance, facilities, board, depreciation, stock compensation, warrant, and public-company costs.
- Net loss improved despite higher operating expenses because the 2014 period included a $2.3 million unfavorable fair-value adjustment related to warrant and other liabilities that had been settled or terminated in connection with the IPO.
- Cash declined substantially during the first six months of 2015 as operating cash burn exceeded financing proceeds.
- Common shares outstanding increased from 12.8 million at December 31, 2014 to 13.2 million at June 30, 2015, primarily reflecting the IPO overallotment and other equity activity.
Guidance, Outlook, Risks, and Unusual Items
- Management expected continuing losses and increasing expenses for at least the next several years, with no significant therapeutic-product revenue expected unless NeoCart or another candidate receives regulatory approval and is commercialized.
- Future spending was expected to increase for clinical trials, manufacturing scale-up and technology transfer, clinical materials, intellectual property, personnel, regulatory activities, and public-company infrastructure.
- Additional equity or debt financing is expected to be necessary. Failure to obtain financing could delay, reduce, or terminate development or commercialization programs and could dilute existing shareholders or impose additional covenants.
- Key risks include clinical-trial enrollment and outcomes, FDA approval, manufacturing and technology-transfer execution, intellectual-property protection, competition, market acceptance and reimbursement, dependence on key personnel and collaborators, and covenant compliance.
- The company had lease commitments through 2023, a $137,000 restricted-cash letter of credit, potential license milestones and royalties, and a remaining $190,000 payment due upon expected 2016 acceptance of a bioreactor system.
- Potential future obligations include a $3.0 million FDA-approval payment under the Hydrogel License, a $300,000 FDA-approval payment under the Tissue Regeneration License, royalties, and other license-related milestone payments.
- The company reported no material pending legal proceedings and no material changes to the risk factors previously disclosed in its 2014 Form 10-K.
Investor Verification Items
- Verify the issuer identity: the supplied filing is Histogenics Corporation, not Ocugen, Inc.
- Review NeoCart Phase 3 enrollment progress, trial results, FDA interactions, and the expected enrollment-completion timeline.
- Reconcile cash burn against the stated expectation that cash would fund operations into 2017 and assess the timing and terms of future financing.
- Review the company’s license milestones, royalty obligations, facility leases, equipment-loan covenants, and remaining capital commitments.
- Assess dilution from outstanding options and warrants, including approximately 918,400 outstanding options and 170,102 warrant shares excluded from diluted loss-per-share calculations.
- Confirm that no revenue-generating product had received regulatory approval and that reported losses and accumulated deficit remained the principal financial condition.